Emergent Biosolutions (NYSE:EBS) Announces Earnings Results, Beats Estimates By $1.45 EPS

Emergent Biosolutions (NYSE:EBS) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $1.45, MarketWatch Earnings reports. Emergent Biosolutions had a net margin of 13.52% and a return on equity of 23.64%. The firm had revenue of $394.70 million during the quarter. Emergent Biosolutions updated its Q3 2020
After-Hours guidance to EPS and its FY 2020
After-Hours guidance to EPS.

NYSE:EBS traded up $14.22 during mid-day trading on Friday, reaching $111.24. The stock had a trading volume of 1,834,419 shares, compared to its average volume of 1,235,720. Emergent Biosolutions has a 12 month low of $39.11 and a 12 month high of $114.13. The stock has a market capitalization of $5.83 billion, a PE ratio of 34.65 and a beta of 1.27. The company has a debt-to-equity ratio of 0.71, a current ratio of 3.03 and a quick ratio of 1.83. The stock has a 50-day simple moving average of $84.58 and a two-hundred day simple moving average of $70.75.

EBS has been the topic of a number of recent research reports. Guggenheim lowered their target price on Emergent Biosolutions from $101.00 to $87.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Cantor Fitzgerald lifted their target price on Emergent Biosolutions from $85.00 to $110.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Chardan Capital boosted their target price on shares of Emergent Biosolutions from $86.00 to $112.00 and gave the company a “buy” rating in a research report on Friday. Argus lifted their price objective on shares of Emergent Biosolutions from $67.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Zacks Investment Research downgraded shares of Emergent Biosolutions from a “hold” rating to a “sell” rating and set a $89.00 price objective for the company. in a report on Wednesday, May 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $90.00.

In related news, Director Zsolt Harsanyi sold 4,940 shares of Emergent Biosolutions stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $81.99, for a total transaction of $405,030.60. Following the sale, the director now directly owns 24,933 shares of the company’s stock, valued at approximately $2,044,256.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronald Richard sold 6,572 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $87.51, for a total transaction of $575,115.72. Following the transaction, the director now owns 4,269 shares of the company’s stock, valued at $373,580.19. The disclosure for this sale can be found here. Insiders have sold 19,887 shares of company stock valued at $1,651,738 over the last 90 days. Corporate insiders own 14.10% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Featured Story: What is the Russell 2000 Index?

Earnings History for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.